Table 1.
Baseline Characteristics of the PD Population
| DM (n = 30) | Non-DM (n = 34) | p Value | |
|---|---|---|---|
| Age, yrs | 61 ± 8 | 56 ± 9 | 0.015 |
| Male | 23 (77) | 23 (67) | 0.579 |
| BMI, kg/m2 | 31 ± 5 | 32 ± 8 | 0.757 |
| Race | 0.487 | ||
| White | 15 (50) | 22 (65) | |
| Black | 14 (47) | 11 (32) | |
| Other | 1 (3) | 1 (3) | |
| Enrollment criteria∗ | 0.002 | ||
| Prior MI | 13 (43) | 28 (82) | |
| PAD | 17 (57) | 6 (18) | |
| CKD | 2 (7) | 2 (6) | 1 |
| Hypertension | 29 (97) | 25 (74) | 0.015 |
| Dyslipidemia | 27 (90) | 22 (65) | 0.020 |
| Active smoking | 10 (33) | 14 (41) | 0.408 |
| CAD | 22 (73) | 30 (88) | 0.199 |
| Prior PCI | 20 (67) | 25 (73) | 0.593 |
| Prior CABG | 7 (23) | 4 (12) | 0.322 |
| Creatinine, mg/dl | 1.1 ± 0.3 | 0.9 ± 0.2 | 0.073 |
| CrCl, ml/min | 102 ± 40 | 117 ± 58 | 0.232 |
| Platelet count, 103/μl | 249 ± 62 | 227 ± 59 | 0.160 |
| Hematocrit, % | 39 ± 4 | 41 ± 4 | 0.182 |
| Hemoglobin, g/dl | 12.9 ± 1.3 | 13.5 ± 1.6 | 0.145 |
| Medications | |||
| Insulin therapy | 16 (53) | 0 (0) | <0.001 |
| OAD | 23 (77) | 0 (0) | <0.001 |
| Beta-blockers | 27 (90) | 30 (88) | 1 |
| ACE inhibitor/ARB | 25 (83) | 21 (62) | 0.093 |
| Statins | 30 (100) | 32 (94) | 0.494 |
Values are mean ± SD or n (%).
ACE = angiotensin-converting enzyme; ARB = angiotensin receptor blocker; BMI = body mass index; CABG = coronary artery bypass graft; CAD = coronary artery disease; CKD = chronic kidney disease; CrCl = creatinine clearance; DM = diabetes mellitus; MI = myocardial infarction; OAD = oral antidiabetic drug; PAD = peripheral arterial disease; PCI = percutaneous coronary intervention; PD = pharmacodynamic.
∗
2 patients categorized as MI also had PAD (see Supplemental Material for definition of study entry criteria).